Companies › Rottapharm Biotech
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Balstilimab (AGEN2034) Programmed cell death protein 1 antagonist | PDCD1 | Phase 1 | Refractory Metastatic Colorectal Cancer | Dec 2026 |
| Vorbipiprant (CR6086) Prostanoid EP4 receptor antagonist | PTGER4 | Phase 1 | Refractory Metastatic Colorectal Cancer | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05205330 | Vorbipiprant (CR6086) | Phase 1 | Refractory Metastatic Colorectal Cancer | Oncology | Dec 2026 |
| NCT05205330 | Balstilimab (AGEN2034) | Phase 1 | Refractory Metastatic Colorectal Cancer | Oncology | Dec 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.